spacer
home > ebr > winter 2001 > prevention and cure - intellectual property due diligence and warranties in biotechnology and pharmaceutical technology transfer agreements
PUBLICATIONS
European Biopharmaceutical Review

Prevention and Cure - Intellectual Property Due Diligence and Warranties in Biotechnology and Pharmaceutical Technology Transfer Agreements

Intellectual property (IP) due diligence is a crucial component of any transaction involving the transfer of technology and associated intellectual property rights. Whether you are raising due diligence requests or responding to requests, there are numerous logistical difficulties and potential pitfalls. This article presents a series of 'frequently asked questions' in the area of intellectual property due diligence and provides practical solutions to those questions. Although the terms 'seller' and 'purchaser' will be used in this article, the principles discussed generally apply equally to a licensor and licensee in the context of agreements such as straight licences, collaboration agreements involving cross-licensing, and joint ventures for exploitation of combined technology.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Daniel Pavin, a Solicitor Specialising in Intellectual Property and
Information Technology Law with UK Law Firm Taylor Joynson Garret

Daniel Pavin is a Solicitor specialising in intellectual property and information technology law. Daniel advises a wide range of clients, with a focus on clients in the pharmaceutical, biotechnology and information technology sectors.
Daniel has a degree from Cambridge University, UK, in Computer Science and Physics, and worked as a computer programmer before qualifying as a Solicitor. He has a Diploma in Intellectual Property Law from Bristol University, UK.

spacer
Daniel Pavin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

H&T Presspart unveil low GWP propellant filling facility

Blackburn, UK- 22nd June 2022 – H&T Presspart’s Inhalation Product Technology Centre (IPTC) is pleased to announce the opening of our laboratory facility to support the development of sustainable metered-dose inhalers with low global warming potential (GWP) propellant.
More info >>

White Papers

eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials

Clinical Ink

Unlike traditional electronic data capture (EDC), SureSource, Clinical Ink’s eSource platform, was designed from the beginning to minimize clinical trial complexity for site users. A Site Impact Survey provides scientific evidence regarding the impact of SureSource from 517 site users. Results confirm it significantly reduces workload, lessens queries, and improves data quality compared to paper and EDC. In this white paper, we quantitatively evaluate survey outcomes, provide qualitative feedback from survey respondents, and highlight the observed benefits of SureSource for transforming clinical research.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement